Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

By LabMedica International staff writers
Posted on 27 Mar 2025

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva. More...

MicroRNAs, which range from 18 to 25 nucleotides in length, are well-established post-transcriptional regulators of gene expression and play a crucial role in intracellular communication. These molecules, present in human biological fluids, are released from both normal and tumor cells, with about 3,000 individual microRNAs identified. These microRNAs circulate within biological fluids, often bound to biopolymers or packed into microvesicles, which makes them relatively stable. As a result, they are considered an ideal source of diagnostic material for liquid biopsies to detect tumors or other pathological conditions. For microRNAs to be utilized effectively as biomarkers, systematic and universally accepted guidelines for biosample processing must be developed, particularly concerning the stability of microRNAs during storage. Now, new research has shown that pre-analytical factors, such as the storage conditions of blood plasma or extracellular vesicles, significantly impact microRNA stability, thereby influencing the detected concentrations of specific microRNAs.

In a study conducted by researchers at the Novosibirsk Institute of Chemical Biology and Fundamental Medicine (ICBFM, Novosibirsk, Russia), the team investigated how different plasma storage conditions affected the stability of endogenous microRNAs in human blood plasma. The study focused on four endogenous microRNAs (miR-16, miR-19b, miR-23a, miR-451a) and the exogenous microRNA cel-miR-39, evaluating their stability under short- and long-term incubation at various temperatures. Additionally, the team examined how long-term storage affected the stability of microRNAs within extracellular vesicles (EVs). They also compared microRNA yields from fresh and archived plasma samples and assessed the impact of variations in miRNA extraction protocols and the use of RNA stabilizing agents on the efficiency of isolation.

The researchers employed a single-phase miRNA isolation method, which they had successfully used in previous studies to identify miRNA biomarkers for lung cancer in blood. Published in the ExRNA journal, the study confirmed that the degradation rate of microRNAs is influenced by their structure and packaging. They also found that adding various stabilization solutions to biofluids can impact the efficiency of miRNA extraction. The long-term findings from this study emphasize the importance of analyzing cell-free nucleic acids, including microRNAs, within 2 to 4 weeks after biological samples are collected to ensure the accuracy and reliability of diagnostic results.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.